Autophagy-mediated selective degradation of GTP cyclohydrolase I couples mitochondrial siege to eNOS uncoupling in senescent endothelium

Hypothesis

In senescent endothelial cells under metabolic siege, autophagy does not indiscriminately recycle bulk cargo; instead, it selectively targets GTP cyclohydrolase I (GCH1), the rate‑limiting enzyme for tetrahydrobiopterin (BH4) synthesis, via the autophagy receptor NIX/BNIP3L. This selective degradation lowers BH4 pools, promoting eNOS uncoupling and superoxide production, which sustains a redox signal that reinforces the senescent inflammatory phenotype while conserving amino acids and GTP for essential SASP components.

Mechanistic Rationale

• The seed idea frames autophagy as a rationing system. BH4 recycling is energetically expensive, requiring GTP, NADPH, and amino acid precursors. When autophagic flux is impaired, mitophagy failure raises ROS, activating DDR/p38 and pushing the cell toward an inflammatory SASP state.
• Recent work shows that senescent ECs exhibit reduced eNOS activity and NO bioavailability due to ROS‑driven BH4 depletion and eNOS uncoupling [2].
• Impaired autophagy also drives cGAS‑STING activation and NF‑κB‑mediated ICAM‑1 upregulation [1].
• We propose that the cell intentionally degrades GCH1 through autophagy to shift limited biosynthetic flux from BH4 production (costly) toward sustaining NF‑κB‑driven SASP/ICAM‑1 expression (more immediately advantageous for immune surveillance).

Testable Predictions

1. Selective GCH1 turnover – In senescent human umbilical vein endothelial cells (HUVECs) induced by oxidative stress (H₂O₂) or disturbed shear, immunoprecipitation of LC3‑II will show increased binding to GCH1 and NIX/BNIP3L compared with proliferating controls.
2. BH4 rescue via autophagy inhibition – Genetic knockdown or pharmacological inhibition of NIX (but not of general autophagy regulators like ULK1) will restore BH4 levels, increase NO production, reduce superoxide, and decrease SASP markers (IL‑6, IL‑8, ICAM‑1) without markedly altering LC3‑II/I ratios or p62 accumulation.
3. SASP dependency – Restoring BH4 (via sepiapterin supplementation) in NIX‑deficient senescent ECs will not further reduce SASP beyond the effect of NIX loss, indicating that GCH1 degradation lies upstream of BH4 depletion in the pathway.
4. In vivo relevance – Mice with endothelial‑specific NIX deletion exposed to angiogenic stress (e.g., femoral artery ligation) will exhibit higher endothelial NO bioavailability, lower ICAM‑1 expression, and improved perfusion recovery compared with wild‑type littermates.

Experimental Approach (brief)

• Cell model: Primary HUVECs treated with 100 µM H₂O₂ for 24 h to induce senescence (validated by SA‑β‑gal, p16^INK4a^ increase).
• Assays: Co‑immunoprecipitation of LC3 with GCH1/NIX; BH4 quantification by HPLC; NO/DAN fluorescence; MitoSOX for superoxide; qPCR/ELISA for SASP cytokines and ICAM-1.
• Interventions: siRNA against NIX, CRISPR‑Cas9 knockout, ULK1 inhibitor (MRT68921) as autophagy flux control, sepiapterin (BH4 precursor) rescue.
• In vivo: Endothelial‑specific NIX^fl/fl^;Cdh5‑CreERT^ mice tamoxifen‑induced, subjected to hind‑limb ischemia; laser Doppler perfusion monitoring, CD31 immunostaining for eNOS uncoupling (eNOS dimer/monomer ratio), ICAM‑1 staining.

Falsifiability

If NIX loss does not alter GCH1‑LC3 interaction, BH4 levels, or NO/superoxide balance in senescent ECs, or if SASP attenuation occurs without changes in BH4, the hypothesis that selective autophagic degradation of GCH1 drives eNOS uncoupling as a siege‑rationing strategy would be refuted. Conversely, confirmation of the predicted mechanistic link would support a refined view of autophagy as a targeted metabolic trade‑off rather than a generic clearance mechanism.